As we look toward 2030, China's Active Pharmaceutical Ingredient (API) industry stands at an inflection point, with transformative forces reshaping its trajectory. Current projections indicate a market size reaching $23.32 billion by 2030, representing a compound annual growth rate (CAGR) of 7.86% from 2025. However, the qualitative evolution of the industry may prove even more significant than its quantitative growth.
Market Size and Growth Projections
The expansion of China's API market is expected to continue robustly through 2030:
According to Mordor Intelligence analysis, the market is projected to grow from $15.97 billion in 2025 to $23.32 billion by 2030, maintaining a CAGR of 7.86% throughout this period.
This growth will be driven by both volume expansion in established API categories and value growth from the increasing proportion of complex, high-value APIs in the product mix.
Technological Evolution
The technological landscape of API manufacturing in China is expected to undergo significant transformation by 2030:
Continuous Manufacturing Dominance: By 2030, continuous manufacturing is projected to account for over 30% of API production in China, up from less than 10% in 2025. This shift will enable higher efficiency, improved quality consistency, and reduced environmental impact.
As we approach 2030, China's API industry is poised for both quantitative growth and qualitative transformation. The projected market size of $23.32 billion represents not merely an expansion of existing capabilities but the emergence of a more sophisticated, innovation-driven, and globally integrated industry.